Semax is one of the most extensively studied neuropeptides in cognitive and neurological research — yet outside of Russia and Eastern Europe it remains relatively unknown to the broader scientific community. Originally developed at the Russian Academy of Sciences in the 1980s, this synthetic heptapeptide has accumulated over three decades of research data covering cognitive function, neuroprotection, neurotrophic signalling, and stroke recovery. This post provides an educational overview of what Semax is and what the current scientific literature tells us about it. All information is provided strictly for educational and research purposes only.
What Is Semax?
Semax is a medication used in Eastern Europe for the treatment of a broad range of conditions including brain trauma, but predominantly for its nootropic, neuroprotective, and neurorestorative effects. Chemically it is a synthetic analogue of a fragment of adrenocorticotropic hormone, first described in scientific literature in 1991 and extensively studied in Russia where it appears on the List of Vital and Essential Drugs. It is a seven amino acid synthetic peptide — Met-Glu-His-Phe-Pro-Gly-Pro — derived from the ACTH(4–10) fragment. The Pro-Gly-Pro tail added to the C-terminus makes it resistant to enzymatic degradation and carries independent pharmacological activity of its own.
Origins and Development
It was first recognised in the 1950s that adrenocorticotropic hormone may have cognitive effects in addition to its hormonal effects. Several derivatives were developed around the N-terminal of ACTH to isolate the cognitive effects of the peptide. In the 1970s a modification to the C-terminal with Pro-Gly-Pro increased its duration of effects to 20 to 24 hours in animal models. Semax was subsequently developed at the Russian Academy of Sciences and has been registered in Russia since 1996.
BDNF Upregulation
One of the most significant findings in Semax research is its ability to upregulate brain-derived neurotrophic factor — BDNF — a protein essential for the growth, maintenance, and survival of neurons. Research has shown that a single intranasal dose produced a 1.4-fold increase in BDNF protein and a 3-fold increase in BDNF mRNA in the rat hippocampus, with a concurrent 1.6-fold increase in TrkB receptor phosphorylation. Binding studies confirmed receptor-mediated binding rather than nonspecific membrane interaction, with the BDNF response being region-specific — concentrated in the basal forebrain rather than diffusely distributed.
Neurotransmitter Modulation
Beyond BDNF, Semax research has documented effects across multiple neurotransmitter systems. Research in rodents demonstrated activation of both dopaminergic and serotonergic brain systems within 30 minutes of intranasal administration. In permanent middle cerebral artery occlusion models, Semax upregulated NGF, NT-3, and their high-affinity receptors including TrkA, TrkB, and TrkC — suggesting a broad neurotrophic profile rather than a single pathway mechanism.
Neuroprotection and Stroke Research
In a rat model of photothrombosis, six daily treatments with Semax after injury reduced infarction size and improved performance on cognitive testing. Semax also reduced neurological damage in a model of cerebral ischaemia caused by gravitation overload and reduced nitric oxide generation post-ischaemia. A genome-wide study investigating the transcriptome response of ischaemised rat brain cortex to Semax found the peptide predominantly enhanced expression of genes related to the immune system — uncovering a neuroprotective mechanism through immune modulation that had not been previously identified.
Cognitive Research
In healthy rats, intranasal and intraperitoneal Semax improved cognition on passive avoidance testing 15 minutes after treatment. Human research has reported improvements in attention and short-term memory, with EEG changes similar to those observed with other neuroprotective compounds. A 2024 study found Semax produced antidepressant-like effects in multiple validated rodent models of depression and anxiety, with efficacy comparable to its PGP tripeptide fragment.
Alzheimer's Disease Research
Some of the most recent Semax research has focused on its potential interactions with amyloid beta — the protein associated with Alzheimer's disease pathology. Research has shown that Semax reduces the total amount of membrane disruption caused by amyloid beta oligomers in a concentration-dependent manner, suggesting it could interfere with oligomeric species responsible for fibre formation. Soluble amyloid beta oligomers are considered the main neurotoxic species in the development of Alzheimer's disease making this a particularly significant area of ongoing investigation.
Spinal Cord Injury Research
A 2025 study identified a previously unknown mechanism — Semax targets the mu opioid receptor gene, promoting deubiquitination and stabilising lysosomal membranes after spinal cord injury. This mechanism is entirely separate from BDNF upregulation or neurotransmitter modulation, suggesting Semax has pharmacological effects beyond what its melanocortin receptor activity would predict.
Calcium Dynamics — 2025 Research
A 2025 study published in the Bulletin of Experimental Biology and Medicine examined Semax's effects on intracellular calcium dynamics. Application of Semax at one micromolar significantly increased the frequency of spontaneous calcium fluctuations in the pyramidal layer cells of the hippocampal CA1 field, providing new insights into the localisation of cellular targets and the dynamics of the initial stages of interaction between the peptide and the hippocampal neuronal network.
Current Research Status
Semax is approved in Russia for ischaemic stroke and cognitive disorders. Recent research has expanded its known mechanisms to include opioid receptor modulation and anti-amyloid effects. The primary limitation is the absence of large-scale Western-standard clinical trials, meaning the translation from strong animal data and limited Russian clinical reports to established therapeutic use outside Russia remains an active area of scientific investigation.
Research Grade Semax from BioSupply UK
BioSupply UK supplies Semax as a research grade compound at 99%+ purity, independently third party lab tested and HPLC verified. Available in 10mg vials with Certificates of Analysis available on request. Strictly for laboratory and in-vitro scientific research only.
This content is provided for educational and research purposes only and does not constitute medical advice. Semax is not approved for human use outside of Russia and should not be used outside of a controlled laboratory research setting.